Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of VNS Vaccine Compared With Varivax in Healthy Children 12 to 15 Months of Age
NCT06693895Phase 3Recruiting
- Sponsor
- GSK
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 8
01
Overview
Phase 3, randomised, single-blind trial of Investigational varicella vaccine in chickenpox (2 arms), sponsored by GSK. Primary endpoints: Percentage of participants reporting each solicited administration site events at Day 43, Percentage of participants reporting each solicited systemic event at Day 43 and 4 more. Started Nov 2024; status: recruiting.
02
Drugs
Investigational varicella vaccine
03
Conditions
chickenpox
Beyond the preview
Go deeper on NCT06693895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693895.